Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or ...

Revaccination at 12 months with the investigational respiratory syncytial virus (RSV) vaccine mRNA-1345 is well tolerated and supported for eligible older adults, according to study results presented ...

A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or ...

The RSV vaccine Abrysvo was highly effective against hospital and ED encounters in a large cohort of older adults with comorbidities and immunocompromising conditions.

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. With U.S ...

Today, we talk about some RSV competition that’s brewing, how Alnylam’s CEO spoke about its plans with ATTR-CM, and more. Alnylam Pharmaceuticals is expanding the footprint of its RNA-based ...

In truth, we know what it is: those newly sprouted sunspots, hyperpigmentation, and melasma signs are often triggered by hot ...

New real-world data suggests that seniors who get the RSV vaccine have an 80% lower odds for severe illness It's yet another reason to get immunized ahead of another RSV season Widespread immunization ...

Respiratory syncytial virus (RSV) is a common, highly contagious illness that affects the nose, throat, and lungs. Although RSV usually causes mild illness with cold-like symptoms, the infection can ...

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections. The antibody ...